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ABSTRACT
Background. The value of the sentinel lymph node (SLN)
procedure in colon cancer patients remains a matter of
debate. The objective of this prospective, multicenter trial
was 3-fold: to determine the identification rate and accu-
racy of the SLN procedure in patients with resectable colon
cancer; to evaluate the learning curve of the SLN proce-
dure; and to assess the extent of upstaging due to the SLN
procedure.
Methods. One hundred seventy-four consecutive colon
cancer patients were enrolled onto this prospective trial.
They underwent an intraoperative SLN procedure with
isosulfan blue 1% injected peritumorally followed by open
standard colon resection with oncologic lymphadenectomy.
Three levels of each SLN were stained with hematoxylin
and eosin (H&E) and immunostained with the pancyto-
keratin marker AE1/AE3 if H&E was negative.
Results. SLN identification rate and accuracy were 89.1%
and 83.9%, respectively. SLN were significantly more
likely to contain tumor infiltrates than non-SLN
(P \ 0.001). Both SLN identification rate (P = 0.021) and
the sensitivity of the procedure (P = 0.043) significantly
improved with experience. The use of immunohistochem-
istry in SLN resulted in an upstaging of 15.4% (16 of 104)
stage I and II patients considered node-negative in initial
H&E analysis.
Conclusions. The SLN procedure for colon cancer has
good identification and accuracy rates, which further
improve with increasing experience. Most importantly, the
SLN procedure results in upstaging of [15% of node-
negative patients. The potential advantage of performing
the SLN procedure appears to be particularly important in
these patients because they may potentially benefit from
adjuvant therapy.
The sentinel lymph node (SLN) principle assumes that
the lymphatic spread of a given cancer occurs in an orderly
centrifugal pattern.1 Therefore, first-tier lymph nodes have
a greater probability of harboring nodal tumor infiltrates
than second or third tier lymph nodes. First-tier lymph
nodes are considered to be the sentinel nodes and therefore
to reflect whether the regional lymph nodes harbor tumor
cells. The identification of one or a few SLNs greatly
facilitates nodal staging in some malignancies (e.g., breast
cancer or malignant melanoma) because the analysis of a
smaller number of lymph nodes is required. Moreover, in
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search of small nodal tumor infiltrates, SLN can be ana-
lyzed more thoroughly, including serial sectioning and the
use of immunohistochemistry (IHC). To perform such
in-depth analyses for all resected lymph nodes would be
prohibitively expensive and time-consuming.
The SLN procedure has gained widespread acceptance
for axillary staging of breast cancer patients.2 It is now well
known that the SLN procedure leads to reduced morbidity,
improved staging, and better outcomes in breast cancer
patients.3,4 However, unlike breast cancer, the SLN pro-
cedure for colon cancer patients is still under investigation
and remains a matter of debate. Only a few multicenter
trials, including one randomized, controlled study, evalu-
ating the procedure have been published so far.5–8 The goal
of performing the SLN procedure in colon cancer patients
is to improve the accurate nodal staging and to facilitate
identification of small nodal tumor infiltrates (B2 mm) in a
time- and cost-effective way. This is particularly important
in patients considered to be node-negative after conven-
tional nodal staging—that is, stage I and II disease
according to American Joint Committee on Cancer (AJCC)
criteria.9 These patients have a potential risk of being
understaged because a relevant fraction of patients harbor
nodal metastases that can be found with careful reexami-
nation of the resected lymph nodes.10–12 Therefore,
hypothetically, the potential benefits of adjuvant therapy on
disease-free and overall survival are withheld from patients
whose disease is understaged. This risk is particularly
important in patients with a low number of reported lymph
nodes—for example, fewer than 12 lymph nodes.13–15 The
SLN procedure has been suggested to improve accurate
nodal staging in colon cancer patients.16
The objective of this prospective, multicenter trial was
3-fold: to determine the identification rate and accuracy of
the SLN procedure for consecutive colon cancer patients;
to analyze the learning curve for the SLN procedure in
colon cancer patients; and most importantly, to assess the
extent of upstaging due to the SLN procedure.
METHODS
Study Settings
This study is a prospective multicenter trial with a
standardized protocol (‘‘Swiss Prospective, Multicenter
Study Sentinel Lymph Node Procedure in Colon Cancer’’).
Three Swiss academic and university-affiliated institutions
enrolled patients from May 2000 through December 2006.
The study was approved by all ethical committees of the
participating centers and was conducted in compliance
with the institutional guidelines for experimental investi-
gation with human subjects as well as according to the
Declaration of Helsinki. All patients provided written
informed consent. The trial has been registered at Clini-
calTrials.gov (NCT00826579).
Patients
Patients with biopsy-proven resectable colon cancer,
AJCC stage I–III, scheduled for open surgery were eligi-
ble.9 Exclusion criteria were distant metastases, rectal
cancers, prior abdominal cancer surgery, history of other
malignancies, allergy to isosulfan blue, pregnancy, and
breast-feeding. In total, 203 patients were considered for
inclusion in this study (Fig. 1). Twenty-nine patients
(14.3%) did not meet the eligibility criteria and were thus
excluded. We therefore report on 174 eligible and evalu-
able patients. Patient characteristics are listed in Table 1.
SLN Procedure
The technique of the SLN procedure was standardized in
the protocol and followed the recommendations described
in detail by Saha et al. as well as by our group.16–18 Briefly,
after careful mobilization of the affected colon segment,
isosulfan blue 1% (median 2.0 ml, range 0.2–10.0 ml;
Lymphazurin 1%, Ben Venue Labs, Bedford, OH; or iso-
sulfan blue USZ 1%, University Hospital of Zurich, Zurich,
Switzerland) was injected in vivo into the subserosa cir-
cumferentially around the tumor with a tuberculin syringe
with 29-gauge needle. The amount of blue dye to be
injected was not specified in the protocol. However, on the
basis of our own data, surgeons tended to inject higher
volumes of blue dye for larger tumors in the second part of
the study.18 Lymph nodes in the mesentery staining blue
during the first 10 min were marked as SLN with a suture.
Only these marked nodes were considered SLN; additional
blue nodes detected later by the pathologist were not
considered SLN. The procedure was followed by a resec-
tion of the affected colon segment with standard oncologic
lymphadenectomy.
Histopathologic Examination
All marked SLN were processed separately as stan-
dardized in the study protocol: Irrespective of lymph node
size, five serial sections of each SLN were obtained at 3
different representative levels. The first section of each
level was stained with hematoxylin and eosin (H&E). If no
metastatic deposits were detectable by H&E, the fourth
section of each level was immunostained with the pancy-
tokeratin marker AE1/AE3 (DakoCytomation, Glostrup,
Denmark). Manual dissection of the fixed surgical speci-
mens was performed to identify the remaining lymph nodes
(non-SLN). The mesentery was sliced at 0.3–0.5 cm
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intervals to allow thorough visual and digital inspection.
Done carefully this gross dissection method will reveal all
lymph nodes 0.3 cm in size and larger. The non-SLN were
bivalved and examined by H&E. If no macrometastases
were found in the SLN or in the non-SLN, all non-SLN
were examined equally to the SLN with step sections and
IHC. All cytokeratin positive cells were confirmed to be
tumor cells by microscopic reevaluation of the immuno-
stained sections after counterstaining with hemalaun.
Staging
Staging was performed according to the 6th edition of
the AJCC staging manual—that is, lymph nodes with mi-
crometastases were considered positive, whereas lymph
nodes with isolated tumor cells were considered negative.9
The definitions of tumor cell infiltrates according to the 6th
edition of the AJCC staging manual were as follows: macrom-
etastases[2.0 mm, micrometastases[0.2 to B2.0 mm, and
isolated tumor cells (ITC) B0.2 mm.9,19 In the present
study, micrometastases and ITC were subsumed as small
nodal tumor infiltrates. Patients considered node-negative
after initial H&E analysis, but in whom small nodal tumor
infiltrates were detected after in-depth analyses (serial
sections and IHC), were considered upstaged—that is, to
22 pts with additional
micro- or macromets
in NSLN
3 pts NSLN with ITC
82 pts NSLN totally
w/o evidence of
tumor deposits
3 pts with
micromets in NSLN
22 pts with
macromets in NSLN
7 pts w/o tumor
deposits in NSLN
= possible upstaging45 pts SLN
with tumor
deposits (TP)
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negative (TN)
110 pts
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eligible
Study
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25 pts SLN
false negative
2 pts with micromets
in SLN = upstaging
14 pts ITC in SLN
= “upstaging”
 (FN)
FIG. 1 Study flow chart. FN false-negative group, ID identification group, ITC isolated tumor cell, mets metastases, NID nonidentification
group, NSLN non–sentinel lymph node, pts patients, SLN sentinel lymph node, TN true-negative group, TP true-positive group, w/o without
TABLE 1 Characteristics of the population
Characteristic Value
Total 174 (100%)
Gender
Male 95 (54.6%)
Female 79 (45.4%)
Age, y, median (range) 74 (27–93)
AJCC stage
I 32 (18.4%)
II 78 (44.8%)
III 64 (36.8%)
Localization of primary tumor
Right hemicolon 75 (43.1%)
Left hemicolon 31 (17.8%)
Sigmoid colon 68 (39.1%)
Center
Center 1 109 (62.6%)
Center 2 38 (21.8%)
Center 3 27 (15.5%)
No. of surgeons
Center 1 7
Center 2 13
Center 3 7
AJCC American Joint Committee on Cancer9
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pN1(mi) (stage III) if micrometastases were detected, or to
pN0(i?) if ITC were found.
Statistical Analysis
For descriptive statistics, median values with ranges are
given. Categorical variables were analyzed with the Fisher’s
exact test. For continuous variables, the Student’s t-test was
used. Possible correlations were analyzed with the two-sided
Pearson correlation. Accuracy ([true-positive ? true-nega-
tive cases]/all cases), sensitivity, specificity, negative and
positive predictive values, and false-negative and false-
positive rates were calculated as described by Walter.20 To
assess the learning curve of the SLN procedure, patients from
each center were assigned to groups according to their date of
surgery; the first 20 patients from each center built one group,
the second 20 patients from each center another, and so forth.
Subsequently, SLN identification rate and sensitivity of the
procedure were calculated for each group, and compared by
Fisher’s exact test. Statistical analyses were performed with
SPSS 13.0 for Macintosh (SPSS, Chicago, IL). A P value of
\0.05 was considered to be significant. All P values were
two-sided.
RESULTS
In the present prospective multicenter study, 174 eligi-
ble and evaluable patients were enrolled. The median age
was 73.7 years with a range from 27.3 to 93.0 years. There
was a light male preponderance (54.6%). The characteris-
tics of the patient sample are given in Table 1.
Identification Rate and Accuracy
At least one SLN was identified in 155 of 174 eligible
patients (identification rate 89.1%; Table 2). In 130 of
these 155 patients the SLN results corresponded to the non-
SLN results—that is, the SLNs were either true-positive or
true-negative for the detection of macrometastasis (accu-
racy of the SLN procedure 83.9%; Table 2). However, in
25 patients (16.1%), SLN showed no macro- or microme-
tastases while non-SLN did (false-negative SLN result).
Additional rates describing the SLN procedure are given in
Table 2.
Technical Details of the SLN Procedure
and Characteristics of the Nodal Staging
In 155 patients with SLN identification, the median
injected volume of isosulfan blue 1% was 2.0 ml
(0.2–10.0 ml). Time to detection of the first SLN ranged
from 0.5 to 22 min, with a median of 5 min. A median of 5
SLN (1–10) were tagged intraoperatively. There was no
correlation between the volume of isosulfan blue injected
and the number of SLN detected (P = 0.288). In seven
patients (4.5%), a single macrometastasis was found in the
SLN. The median number of all lymph nodes analyzed (SLN
and non-SLN) in this study was 24 (5–62). Only five patients
(3.2%) had fewer than the minimum required number of 12
lymph nodes described in the pathology report.15 In total,
4000 lymph nodes were analyzed. Of those, 562 (14.1%)
were SLN, and 3438 (85.9%) were non-SLN. Forty-nine
(8.7%) of 562 SLN were found to have nodal metastases by
H&E, and 31 (5.5%) of 562 by IHC. Of 3438 non-SLN, 149
(4.3%) were positive by H&E and 11 (0.3%) of 3438 by IHC.
Therefore, SLN were significantly more likely to harbor
nodal tumor infiltrates compared to non-SLN, based on both
diagnosis by H&E (P \ 0.001) and IHC (P \ 0.001). No
SLN procedure related complications (e.g., allergic reac-
tions) were reported in any of the patients.
Upstaging
To assess a potential upstaging due to the SLN proce-
dure, we analyzed 104 patients who were node-negative in
initial H&E analysis at three levels (stage I and II patients
according to conventional analysis). In 16 of these patients
(15.4%), small nodal tumor infiltrates (micrometastases or
isolated tumor cells) were found in the SLN by multilevel-
sectioning and the use of IHC (Table 3). These patients
were upstaged to pN1(mi) or pN0(i?), respectively.9 In six
additional patients (5.8%), small nodal tumor infiltrates
were found in non-SLN only. However, this upstaging
cannot be attributed to the SLN procedure because these
additional small nodal tumor infiltrates were found in the
non-SLN but not in the SLN.
Learning Curve
The learning curve was calculated by patients’ groups of
20 each, according to their date of surgery as described in
the method section (Table 4). SLN identification rate
TABLE 2 Results of the SLN procedure
Result n/N %
Identification rate 155/174 89.1
Accuracy 130/155 83.9
Sensitivity 31/56 55.4
False-negative rate 25/56 44.6
Specificity 99/99 100.0
False-positive rate 0/99 0.0
Negative predictive value 99/124 79.8
Positive predictive value 31/31 100.0
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significantly improved with center experience (P = 0.021),
as did the sensitivity of the SLN procedure (P = 0.043)
with a SLN identification rate of 98% and a sensitivity of
85% if the center experience exceeds 60 procedures.
DISCUSSION
The findings of the present Swiss prospective, multi-
center study provide compelling evidence that the in vivo
SLN procedure for colon cancer has good identification
and accuracy rates. Most importantly, the SLN procedure
results in upstaging of [15% of node-negative patients.
The potential advantage of performing the SLN procedure
appears to be particularly important in node-negative
patients as they may benefit from adjuvant therapy.
With a median of 24 analyzed lymph nodes per patient,
nodal staging was excellent in our study. Only five patients
(3.2%) had fewer than the minimal required 12 lymph nodes
assessed.15 These favorable lymph node counts could be
caused in part by trial awareness by the participating sur-
geons and pathologists as well as the fact that blue staining
was used. However, a posthoc analysis at one of the par-
ticipating centers (center 1) did not show a significant
change in lymph node yields for patients operated on for
colon cancer before and after the initiation of the study (data
not shown). Our data compare favorably with findings from
the Surveillance, Epidemiology and End Results cancer
registry, where a median of only nine lymph nodes were
identified.21 Moreover, the number of retrieved lymph nodes
in the present investigation clearly exceeds the lymph node
harvest from the randomized, controlled COST trial, in
which 872 colon cancer patients were randomized to open
versus laparoscopic colon cancer resection and only 12
lymph nodes were found both in the open and laparoscopic
group.22 The lymph node harvest in our investigation rep-
resents an important quality indicator of properly performed
surgical oncologic resections as well as meticulous patho-
logic analysis in our consecutive sample of colon cancer
patients. An excellent nodal staging leaves little room for
improvement; nonetheless,[15% of stage I and II patients
were upstaged with the SLN procedure in the present
investigation. This is the most relevant finding of our pro-
spective, multicenter study. The upstaging of stage I and II
colon cancer patients was even higher in the Dutch and the
German multicenter trials.7,8 In a recently published sys-
tematic review, a mean upstaging of 15% of node-negative
patients after conventional histopathologic analysis was
found.14 Patients who are upstaged as a result of the SLN
procedure may constitute a population at higher risk of
recurrence within the stage I and II subset.14 Hypothetically,
these patients might benefit from adjuvant therapy. How-
ever, while this issue has not yet been proven, it is currently
under investigation in a Dutch randomized, controlled trial
(En Route Trial, NCT01097265).23
American Society of Clinical Oncology and National
Comprehensive Cancer Network guidelines now recom-
mend adjuvant chemotherapy to be considered in high-risk
stage II patients with one or several of the following fea-
tures: pT4 tumor, poor differentiation of the primary tumor,
fewer than 12 lymph nodes analyzed, presence of lym-
phovascular invasion, localized perforation, and bowel
obstruction.15,24 Although 13 (17.8%) of 73 stage II
patients in our study showed small tumor infiltrates in the
SLN, only 5 (38.5%) of 13 of these patients had features
that now prompt the consideration of adjuvant chemo-
therapy; all other patients (8 of 13, 61.5%) with small nodal
tumor infiltrates would have missed out on this possibly
beneficial treatment.
Moreover, seven patients (4.5%) in our study had only a
single macrometastasis in the SLN, a situation referred to
as ‘‘possible upstaging.’’ Because the lymph nodes con-
taining the single metastasis might be missed by the
pathologist if only a few lymph nodes are analyzed, the
SLN procedure possibly contributed to the correct nodal
staging in these patients as well.
Some oncologists have stated concerns about the safety
of the SLN procedure, particularly regarding the in vivo
injection of isosulfan blue. However, in the present study,
TABLE 3 Detection of small tumor infiltrates in sentinel lymph
nodes of node-negative patients in initial H&E analysis (patients with
stage I and II disease)
Stage Micrometastases, n Isolated tumor cells, n Total
I 2 1 3/31 (9.7%)
II – 13 13/73 (17.8%)
Total 2 14 16/104 (15.4%)
Patients with micrometastases were upstaged to stage III according to
the 6th edition of the American Joint Committee on Cancer staging
manual9; patients with isolated tumor cells were ‘‘upstaged’’ from
pN0 to pN0(i?)
TABLE 4 Learning curve of the SLN procedure
No. of cases SLN identification rate Sensitivity
1–20 80.0% 42.9%
21–40 88.9% 68.4%
41–60 95.0% 60.0%
B61 98.0% 85.0%
P 0.021 0.043
Patients from each center were assigned to groups according to their
date of surgery; the first 20 patients from each center built one group
(cases 1–20), the second 20 patients another (cases 21–40), and so
forth. It is noteworthy that only center 1 enrolled more than 40
patients onto the study; therefore, ‘‘cases 41–60’’ and ‘‘cases C61’’
represent the learning curve of a single center
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no SLN procedure-related complications were observed.
Therefore, we provide compelling evidence that the per-
formance of the intraoperative SLN procedure in colon
cancer patients is not harmful.
The results of the present investigation underline the
important learning curve for the in vivo SLN procedure in
colon cancer patients. Both SLN identification as well as
the sensitivity significantly increased with higher center
experience. In fact, if more than 60 procedures were per-
formed, the identification rate was close to 100% with a
sensitivity of 85%. It is thus crucial that a surgeon with
expertise in the SLN procedure supervises a beginner to
achieve good results and obtain maximal benefits. Alter-
natively, a dedicated person might perform an ex vivo SLN
procedure after the resection of the affected colon segment.
However, because we performed exclusively the in vivo
SLN procedure in this study, we cannot compare the two
methods. Moreover, despite a good identification rate at the
end of the learning curve with only 15% false-negative
SLN, this false-negative rate is still too high to exclusively
identify and analyze SLN. Thus, this procedure certainly
leads to a better staging in colon cancer patients; however,
the performance of a more limited colon cancer resection
that is based on the SLN remains clearly investigational.
Surprisingly, identification rates as well as the sensi-
tivity of the SLN procedure are lower in the German study
and in the present multicenter trial compared to some
investigations from the United States.6,7,25 Indeed, Bem-
benek et al. (identification rate 85%, sensitivity 54%)
reported similar results to our study (identification rate
89%, sensitivity 55.4%).7 The identification rate in the
investigations from Bilchik et al. and Saha et al. are close
to 100% with a sensitivity of approximately 90%. The
reason for this phenomenon—a European versus a U.S.
pattern—remains to be elucidated.6,25
It is interesting that the ratio of micrometastases versus
isolated tumor cells (ITC) is clearly lower in this pro-
spective trial compared to the German multicenter study or
a large investigation from the United States.7,10 The reason
for this observation remains unclear. Regardless, colon
cancer patients undergoing a SLN procedure who are found
to be negative even after ultrastaging (serial sectioning of
SLN and use of IHC in addition to standard H&E) repre-
sent a subset of patients with excellent prognosis.10
Through a more thorough staging, the SLN procedure
allows for a more accurate prognostic classification of
stage I and II colon cancer patients (e.g., truly node-neg-
ative patients). Therefore, performing the SLN procedure
in colon cancer patients has both therapeutic and prog-
nostic implications.
In conclusion, the SLN procedure for colon cancer has
good identification and accuracy rates, which further
improve with increasing experience. Most importantly, the
SLN procedure results in upstaging of [15% of patients
with stage I and II disease. The potential advantage of
performing the SLN procedure appears to be particularly
important in these patients because they may benefit from
adjuvant chemotherapy.
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